Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sunshine Biopharma (SBFM) Goodwill & Intangibles (2016 - 2025)

Historic Goodwill & Intangibles for Sunshine Biopharma (SBFM) over the last 8 years, with Q3 2025 value amounting to $2.1 million.

  • Sunshine Biopharma's Goodwill & Intangibles fell 3032.49% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year decrease of 3032.49%. This contributed to the annual value of $3.1 million for FY2024, which is 11733.25% up from last year.
  • Latest data reveals that Sunshine Biopharma reported Goodwill & Intangibles of $2.1 million as of Q3 2025, which was down 3032.49% from $2.7 million recorded in Q2 2025.
  • Sunshine Biopharma's 5-year Goodwill & Intangibles high stood at $3.3 million for Q1 2025, and its period low was $776856.0 during Q4 2022.
  • In the last 4 years, Sunshine Biopharma's Goodwill & Intangibles had a median value of $2.1 million in 2024 and averaged $2.1 million.
  • As far as peak fluctuations go, Sunshine Biopharma's Goodwill & Intangibles surged by 14358.26% in 2024, and later tumbled by 3032.49% in 2025.
  • Over the past 4 years, Sunshine Biopharma's Goodwill & Intangibles (Quarter) stood at $776856.0 in 2022, then skyrocketed by 85.91% to $1.4 million in 2023, then surged by 117.33% to $3.1 million in 2024, then plummeted by 32.55% to $2.1 million in 2025.
  • Its last three reported values are $2.1 million in Q3 2025, $2.7 million for Q2 2025, and $3.3 million during Q1 2025.